抗生素抑制皮肤T细胞淋巴瘤肿瘤及疾病活动
这项前瞻性研究纳入8例晚期皮肤T细胞淋巴瘤(CTCL)患者,探索短暂强力抗生素治疗对肿瘤细胞和疾病活动的影响。所有患者临床症状均显著改善,部分改善持续超过8个月;6例可识别恶性T细胞克隆的患者中,抗生素治疗后恶性T细胞比例显著下降,并伴CD25、STAT3信号及细胞增殖表达降低。研究提示强力抗生素治疗可抑制病灶皮肤中的恶性T细胞。
要点
- 8例晚期CTCL患者接受短暂强力抗生素治疗后临床症状均显著改善。
- 部分患者临床改善持续超过8个月。
- 6例可识别恶性T细胞克隆者中,抗生素治疗后恶性T细胞比例显著下降。
核心结论
- 本研究提供新证据提示强力抗生素治疗可抑制病灶皮肤中的恶性T细胞,并为晚期CTCL中治疗金黄色葡萄球菌(SA)提供了新理由。
研究设计与样本
- 前瞻性研究,纳入8例晚期CTCL患者,探讨短暂抗生素治疗对肿瘤细胞和疾病活动的影响。
主要发现
- 所有患者对强力短暂抗生素治疗均出现临床症状显著减轻。
- 部分患者临床改善持续超过8个月。
- 8例中6例在病灶皮肤可识别恶性T细胞克隆,抗生素治疗后恶性T细胞比例显著下降,而其他治疗方案未变。
- 免疫组化、全局信使RNA表达和细胞信号通路分析显示,短暂强力抗生素治疗与病灶皮肤中白介素-2高亲和力受体(CD25)、STAT3信号及细胞增殖表达降低相关。
临床怎么用
- 研究结果提示对晚期CTCL患者可考虑针对金黄色葡萄球菌(SA)进行抗生素治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has been proposed that CD4 T-cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in 8 patients with advanced-stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In 6 of 8 patients, a malignant T-cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global messenger RNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.
引用
- Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019. PMID: 31331920. doi:10.1182/blood.2018888107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。